

S1 Table. Univariate and multivariate analysis for OS and PFS in all patients

	Univariate analysis						Multivariate analysis					
	OS			PFS			OS			PFS		
	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value
Age (yr)												
< 65	1			1			1			1		
≥ 65	1.01	0.78-1.28	0.96	0.90	0.70-1.13	0.37	0.96	0.74-1.23	0.76	0.81	0.63-1.02	0.08
Sex												
Female	1			1			1			1		
Male	0.82	0.63-1.05	0.12	0.92	0.71-1.16	0.48	0.79	0.61-1.02	0.08	0.87	0.67-1.11	0.26
Location												
Colon/S-colon	1			1			1			1		
Rectum	0.97	0.75-1.25	0.82	0.83	0.65-1.06	0.15	1.12	0.86-1.45	0.39	1.00	0.77-1.28	0.98
Histological type												
Well/Moderate differentiation	1			1			1			1		
Poorly differentiation/ Mucinous/ Signet ring cell	1.36	0.97-1.88	0.07	1.19	0.86-1.63	0.28	1.33	0.95-1.85	0.10	1.05	0.76-1.44	0.77
Metastatic presentation												
Metachronous	1			1			1			1		
Synchronous	0.95	0.74-1.23	0.72	0.94	0.73-1.20	0.63	1.37	1.03-1.81	0.03	1.27	0.96-1.66	0.09
Number of metastatic organs												
Only one (1)	1			1			1			1		
More than one (≥2)	1.13	0.88-1.43	0.33	1.27	1.00-1.60	0.04	1.11	0.86-1.42	0.41	1.32	1.04-1.68	0.02
First line chemotherapy												
FOLFOX/ FOLFIRI	1			1			1			1		
FOLFOX/ FOLFIRI+target	0.68	0.50-0.91	0.01	0.64	0.48-0.84	0.002	0.78	0.57-1.05	0.11	0.72	0.54-0.95	0.02

agent

CEA-response

CEA-CR	1			1			1			1		
CEA-PR	1.88	1.21-2.89	0.004	1.49	1.01-2.19	0.04	1.69	1.08-2.61	0.02	1.34	0.90-1.99	0.14
CEA-SD	3.94	2.53-6.11	<0.001	3.02	2.01-4.52	<0.001	4.25	2.70-6.67	<0.001	3.42	2.33-5.00	<0.001
CEA-PD	7.66	4.78-12.2	<0.001	6.03	3.32-9.29	<0.001	7.72	4.79-12.4	<0.001	5.84	3.95-8.61	<0.001

OS, overall survival; PFS, progression-free survival; HR, hazards ratio; CI, confidence interval; FOLFOX, oxaliplatin plus fluorouracil and leucovorin; FOLFIRI, cetuximab plus irinotecan, fluorouracil, and leucovorin; CEA, carcinoembryonic antigen; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.